Antibodies Against Phosphorylcholine in Prediction of Cardiovascular Disease Among Women: A Population-Based Prospective Cohort Study.

Background: Antibodies against phosphorylcholine (anti-PC) have been reported as associated with protection against atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory diseases. Underlying potential mechanisms have been demonstrated and include anti-inflammatory, clearance of dead cells, and inhibition of oxidized low-density lipoprotein effects.

Objectives: This study examined the role of IgM anti-PC and incident CVD among women, where less is known than among men in the general population.

Methods: In a total of 932 women, age 66 ± 6 years at baseline, from the population-based Swedish Mammography Cohort, IgM anti-PC levels of sera were measured using Enzyme Linked Immunosorbent assay. Prospective associations with any first CVD, ischemic heart disease (IHD), myocardial infarction (MI), and ischemic stroke were assessed using Cox proportional hazard regression, generating HRs and 95% CIs. The model was adjusted for potential confounding factors.

Results: Over the course of 16 years (13,033 person-years), we identified 113 cases of composite CVD, 69 cases of IHD, 44 cases of MI, and 50 cases of ischemic stroke. IgM anti-PC was statistically significantly inversely associated with risk of CVD, IHD, and MI, but not with ischemic stroke. Comparing the highest tertile with lowest, we observed multivariable-adjusted HR of 0.27 (95% CI: 0.11-0.68; trend <0.01) for MI.

Conclusions: IgM anti-PC may play an active role in inhibition of CVD development in women, especially MI. Furthermore, IgM anti-PC levels may play a role in identifying those at risk.